Fentanyl Freight Fiasco: CBP Hounds Unsniff Out 215 Pounds in SUV at Otay MesaNone
None
Perovskite solar cell stability doubles with protective coating
Brentford boss Thomas Frank claimed Brighton forward Joao Pedro should have been sent off during his side’s goalless Premier League draw at the Amex Stadium. Pedro escaped punishment after swinging an arm at Bees substitute substitute Yehor Yarmoliuk without making contact. VAR reviewed the second-half incident but deemed there was no violent conduct. Frank and Brighton head coach Fabian Hurzeler disagreed about the decision. “As I understand the rules, you can’t swing your arm to try to hit someone,” said Frank. “If you hit them or not, it’s a red, that’s the way I understand the rules.” Frank spoke to the match officials, including referee Andy Madley, about the flashpoint at full-time. “They haven’t seen the situation yet, not on TV afterwards,” said Frank. “To be fair to him, I think the angle can be tricky so that’s why you’ve got VAR.” Asked about Frank’s assessment, Hurzeler replied: “Interesting opinion. I see it completely different. “For me, it’s not a red card. He tried to get free from a person.” Brighton were booed off after their winless run was stretched to six top-flight games. Albion dominated for large periods and hit the woodwork inside four minutes through Julio Enciso. Bees goalkeeper Mark Flekken made some important saves before being forced off injured in the 36th minute, albeit his replacement Hakon Valdimarsson was rarely tested on his Premier League debut. The Seagulls remain 10th ahead of Monday’s trip to Aston Villa, with Brentford a position and two points below moving towards their New Year’s Day showdown with Arsenal. Hurzeler thought the jeers at full-time were unfair. “The team doesn’t deserve that because in all the games we had in the last weeks they were all good, they were all intense, they were all where we thought we deserved more” said the German, whose team have lost to Fulham and Crystal Palace and drawn with Southampton, Leicester and West Ham in recent matches. “We try to work hard to satisfy our supporters, we try to give them what they deserve, we try to make them proud. “But the Premier League is tough. We know there will be (tough) periods we have to go through, especially with this young squad. “We try to stick together, find the positive and keep on going.” Brentford, who remain without a top-flight away win this term, had an early Yoane Wissa finish ruled out for offside following VAR intervention but barely threatened, despite an improved second-half showing. Frank, who is awaiting news on Flekken and defender Ben Mee, who also left the field injured, said: “I thought it was a fair point. “Brighton were better in the first half, no big, clearcut chances, and I thought we were better second half. “Overall, I’m happy with the performance, especially the way we defended. “We haven’t had too many clean sheets this season, so in that context I thought it was very impressive against a good Brighton team. “We know we have a lot of players out – we get two more injuries during the game. “The way the players showed their mentality and character and dug in was hugely impressive.”CRANFORD, N.J. , Dec. 27, 2024 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for the fiscal full year ended September 30, 2024 . Fiscal Full Year 2024 Business Highlights and Subsequent Developments Achieved U.S. Food and Drug Administration (FDA) approval of LYMPHIRTM (denileukin diftitox-cxdl), an immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL); Began trading on the Nasdaq exchange under the ticker symbol CTOR on August 13, 2024 , following completion of the merger of Citius Pharma's oncology subsidiary with TenX Keane to form Citius Oncology, Inc., a standalone publicly traded company; Advanced manufacturing, marketing and sales activities in preparation for commercial launch of LYMPHIR in the first half of 2025; key activities included: Manufactured initial inventory for launch and finalized supply chain agreements, Initiated recruitment of targeted field force with contract sales organization, Launched a marketing awareness campaign and engaged with all leading CTCL prescribers, Applied for a unique J-code within the Healthcare Common Procedure Coding System (HCPCS) to facilitate accurate reimbursement, Secured inclusion of LYMPHIR in the National Comprehensive Cancer Network (NCCN) guidelines, critical to clinical decision-making in oncology and hematology, influencing treatment practices and payor reimbursement in the U.S., and Initiated development of the patient support center to help patients access LYMPHIR expeditiously; Supported two investigator-initiated trials to explore LYMPHIR's potential as an immuno-oncology combination therapy being conducted at the University of Pittsburgh Medical Center and the University of Minnesota ; and, Shared interim trial results with the clinical community at the Society for Immunotherapy of Cancer Conference (SITC) of University of Pittsburgh Medical Center's Phase I trial of LYMPHIR with checkpoint inhibitor pembrolizumab. The combination of these two immunomodulatory agents showed clinical benefit in relapsed or refractory gynecological neoplasms, resulting in: 27% objective response rate and 33% clinical benefit rate with median progression free survival of 57 weeks (range: 30-96 weeks), and A manageable safety profile whereby the regimen was well-tolerated with reversible treatment emergent adverse events and no definitive immune-related adverse events greater than or equal to grade 3 documented. Financial Highlights R&D expenses were $4.9 million for the full year ended September 30, 2024 , compared to $4.2 million for the full year ended September 30, 2023 ; G&A expenses were $8.1 million for the full year ended September 30, 2024 , compared to $5.9 million for the full year ended September 30, 2023 ; Stock-based compensation expense was $7.5 million for the full year ended September 30, 2024 , compared to $2.0 million for the full year ended September 30, 2023 ; and, Net loss was $21.1 million , or ($0.31) per share for the full year ended September 30, 2024 compared to a net loss of $12.7 million , or ($0.19) per share for the full year ended September 30, 2023 . "Reflecting on 2024, Citius Oncology has achieved pivotal milestones that underscore our commitment to advancing cancer therapeutics," stated Leonard Mazur , Chairman and CEO of Citius Oncology. "The FDA's approval of LYMPHIR for the treatment of cutaneous T-cell lymphoma marks a significant advancement in providing new options for patients battling this challenging disease. It is the only targeted systemic therapy approved for CTCL patients since 2018 and the only therapy with a mechanism of action that targets the IL-2 receptor. Additionally, the successful merger forming Citius Oncology, now trading on Nasdaq under the ticker CTOR, strengthens our position in the oncology sector. We expect it to facilitate greater access to capital to fund LYMPHIR's launch and the Company's future growth. With a Phase I investigator-initiated clinical trial combining LYMPHIR with pembrolizumab demonstrating promising preliminary results, indicating potential for enhanced treatment efficacy in recurrent solid tumors, and preliminary results expected from a second investigator trial with CAR-T therapies in 2025, we remain excited about the potential of LYMPHIR as a combination immunotherapy." "These accomplishments reflect the dedication of our team and the trust of our investors. As we look ahead, we remain steadfast in our mission to develop innovative therapies that improve the lives of cancer patients worldwide," added Mazur. FULL YEAR 2024 FINANCIAL RESULTS: Research and Development (R&D) Expenses R&D expenses were $4.9 million for the full year ended September 30, 2024 , compared to $4.2 million for the full year ended September 30, 2023 . The increase reflects development activities completed for the resubmission of the Biologics License Application of LYMPHIR in January 2024 , which were associated with the complete response letter remediation. General and Administrative (G&A) Expenses G&A expenses were $8.1 million for the full year ended September 30, 2024 , compared to $5.9 million for the full year ended September 30, 2023 . The increase was primarily due to costs associated with pre-commercial and commercial launch activities of LYMPHIR including market research, marketing, distribution and drug product reimbursement from health plans and payers. Stock-based Compensation Expense For the full year ended September 30, 2024 , stock-based compensation expense was $7.5 million as compared to $2.0 million for the prior year. The primary reason for the $5.5 million increase was due to the amounts being realized over 12 months in the year ended September 30, 2024 , as compared to three months post-plan adoption in the year ended September 30, 2023 . Net loss Net loss was $21.1 million , or ($0.31) per share for the year ended September 30, 2024 , compared to a net loss of $12.7 million , or ($0.19) per share for the year ended September 30, 2023 . The $8.5 million increase in net loss was primarily due to the increase in our operating expenses. About Citius Oncology, Inc. Citius Oncology specialty is a biopharmaceutical company focused on developing and commercializing novel targeted oncology therapies. In August 2024 , its primary asset, LYMPHIR, was approved by the FDA for the treatment of adults with relapsed or refractory CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million , is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology's competitive positioning. Citius Oncology is a publicly traded subsidiary of Citius Pharmaceuticals. For more information, please visit www.citiusonc.com Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Oncology. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated, and, unless noted otherwise, that apply to Citius Oncology are: our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to commercialize LYMPHIR and any of our other product candidates that may be approved by the FDA; the estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact the quality of life of our target patient populations; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; risks related to research using our assets but conducted by third parties; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at www.sec.gov , including in Citius Oncology's Annual Report on Form 10-K for the year ended September 30, 2024 , filed with the SEC on December 27, 2024 , as updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. Investor Contact: Ilanit Allen ir@citiuspharma.com 908-967-6677 x113 Media Contact: STiR-communications Greg Salsburg Greg@STiR-communications.com -- Financial Tables Follow – CITIUS ONCOLOGY, INC. CONSOLIDATED BALANCE SHEETS SEPTEMBER 30, 2024 AND 2023 2024 2023 Current Assets: Cash and cash equivalents $ 112 $ — Inventory 8,268,766 — Prepaid expenses 2,700,000 7,734,895 Total Current Assets 10,968,878 7,734,895 Other Assets: In-process research and development 73,400,000 40,000,000 Total Other Assets 73,400,000 40,000,000 Total Assets $ 84,368,878 $ 47,734,895 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable $ 3,711,622 $ 1,289,045 License payable 28,400,000 — Accrued expenses — 259,071 Due to related party 588,806 19,499,119 Total Current Liabilities 32,700,429 21,047,235 Deferred tax liability 1,728,000 1,152,000 Note payable to related party 3,800,111 — Total Liabilities 38,228,540 22,199,235 Stockholders' Equity: Preferred stock - $0.0001 par value; 10,000,000 shares authorized: no shares issued and outstanding — — Common stock - $0.0001 par value; 100,000,000; 71,552,402 and 67,500,000 shares issued and outstanding at September 30, 2024 and 2023, respectively 7,155 6,750 Additional paid-in capital 85,411,771 43,658,750 Accumulated deficit (39,278,587) (18,129,840) Total Stockholders' Equity 46,140,339 25,535,660 Total Liabilities and Stockholders' Equity $ 84,368,878 $ 47,734,895 CITIUS ONCOLOGY, INC. CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023 2024 2023 Revenues $ — $ — Operating Expenses: Research and development 4,925,001 4,240,451 General and administrative 8,148,929 5,915,290 Stock-based compensation – general and administrative 7,498,817 1,965,500 Total Operating Expenses 20,572,747 12,121,241 Loss before Income Taxes (20,572,747) (12,121,241) Income tax expense 576,000 576,000 Net Loss $ (21,148,747) $ (12,697,241) Net Loss Per Share – Basic and Diluted $ (0.31) $ (0.19) Weighted Average Common Shares Outstanding – Basic and Diluted 68,053,607 67,500,000 CITIUS ONCOLOGY, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023 2024 2023 Cash Flows From Operating Activities: Net loss $ (21,148,747) $ (12,697,241) Adjustments to reconcile net loss to net cash provided by operating activities: Stock-based compensation expense 7,498,817 1,965,500 Deferred income tax expense 576,000 576,000 Changes in operating assets and liabilities: Inventory (2,133,871) - Prepaid expenses (1,100,000) (5,044,713) Accounts payable 2,422,577 1,196,734 Accrued expenses (259,071) (801,754) Due to related party 14,270,648 14,805,474 Net Cash Provided By Operating Activities 126,353 - Cash Flows From Investing Activities: License payment (5,000,000) - Net Cash Used In Investing Activities (5,000,000) - Cash Flows From Financing Activities: Cash contributed by parent 3,827,944 - Merger, net (2,754,296) - Proceeds from issuance of note payable to related party 3,800,111 - Net Cash Provided By Financing Activities 4,873,759 - Net Change in Cash and Cash Equivalents 112 - Cash and Cash Equivalents – Beginning of Year - - Cash and Cash Equivalents – End of Year $ 112 $ - Supplemental Disclosures of Cash Flow Information and Non-cash Activities: IPR&D Milestones included in License Payable $ 28,400,000 $
outboundIQ Achieves Certified Implementation Partner (CIP) Status with Five9
Here's what the H-1B visa debate with Musk and Ramaswamy is aboutSpecial counsel moves to dismiss election interference and classified documents cases against TrumpCentury-old department store Nordstrom has agreed to be acquired and taken private by Nordstrom family members and a Mexican retail group in a $6.25 billion deal with the industry being squeezed by discount chains and other competition. Public companies are under a lot more scrutiny and if private, the Nordstrom may have more leeway in reviving a department store chain that has been attempting to reinvigorate sales for years. Javascript is required for you to be able to read premium content. Please enable it in your browser settings. Get our free email newsletters — latest headlines and e-edition notifications.
Michigan aims to cap lost season by beating Ohio StatePresident-elect Donald Trump has pledged to impose significant tariffs on Canada's, Mexico's, and China's imports, following through on his campaign promises despite potential trade war implications. Trump's plan includes a 25% tariff on Canada and Mexico to address border issues like drug smuggling and migrant crossings. The announcement comes as part of Trump's economic agenda to 'put America first,' sparking discussions with Canadian Prime Minister Justin Trudeau and causing fluctuations in the forex and stock markets. The tariffs could challenge the U.S.-Mexico-Canada Agreement, potentially inviting renegotiations ahead of its 2026 review. China responded critically, emphasizing the mutual benefits of trade cooperation and dismissing the suggestion of allowing drug flow into the U.S. Critics warn these tariffs could elevate import duty rates to historical highs, impacting global trade dynamics significantly. (With inputs from agencies.)
Ravens QB Jackson leads first NFL Pro Bowl fan voting results
President-elect Donald Trump 's campaign promises have many wondering how his second presidency will impact everything from the economy to foreign affairs, but the youngest generation appears to be most optimistic about Trump's housing policies. In a new report from ConsumerAffairs, 39 percent of voters said they expected mortgage rates to improve under Trump's presidency. However, by generation, Gen Z was by far the most optimistic, at 44 percent. That's compared to 39 and 27 percent of millennials and Gen X respectively who said the same in the survey of 1,000 voters. Kevin Thompson, a finance expert and the founder and CEO of 9i Capital Group, said Gen Z's optimism might be rooted in the naivety of youth rather than Trump's campaign. "Gen Z tends to focus on the present, often lacking the life experience to recognize that political promises are rarely fulfilled," Thompson told Newsweek . "Trump's rhetoric about lowering housing prices was just that—rhetoric. Housing prices are largely driven by supply and demand, factors that no president directly controls." Altogether, 43 percent of voters said Trump's policies will make homeownership more accessible for aspiring buyers, and one-third postponed a major financial decision while awaiting the election results. This might not be attached to the real economic reality, however, Thompson said. "Americans are overly optimistic if they believe long-term interest rates will drop significantly on their own," Thompson said. "With the U.S. grappling with an ever-growing debt burden, the bond market is signaling that fiscal discipline is needed. It's effectively choking off long-term borrowing until the country gets its financial house in order." Instead, Thompson said today's higher interest rates reflect the "new normal." "Gen Z grew up expecting near-zero rates indefinitely—an artificial condition that is now a key reason why housing has become so unaffordable," Thompson said. When it came to the economy, however, voters were still more concerned about its future (47 percent) than optimistic (44 percent). Alex Beene, a financial literacy instructor for the University of Tennessee at Martin, said for many Gen Z-ers, the only economic comparison they have in their working years is the first Trump administration and Biden's presidency. "President Trump has stated his goal numerous times before and after the election of returning interest rates to where they were during his first term," Beene told Newsweek . "The reason why Americans outside of Gen Z may not be as optimistic is they've lived through more presidencies and realize there are many more factors at play with interest rates than who's in the White House." Realtor.com Chief Economist Danielle Hale previously told Newsweek Trump's impact on the housing market was a "toss-up," saying the chief problem is the lack of supply. There has been a shortage of between 2.5 and 7.2 million homes over the last decade, according to Realtor.com. "The Republican Party platform and President-elect Trump on the campaign trail acknowledged these challenges, shining a light on problems that many voters face daily," Hale said. "The proposals to tackle these challenges, however, are likely to have a mix of good and unintended, but negative, consequences for the housing market." Trump said previously he wanted to get rid of "unnecessary" housing development regulations, which can add more than $90,000 to the price of a new home. Trump and the Republican Party have also discussed making federal lands available for housing development. Still, there are concerns over how Trump's proposed tariffs could disrupt the larger housing market. "Falling mortgage rates would unlock homeowners who currently find moving untenable because their existing mortgage rate is so much lower than the market rate and also improve prospects for buyers by amplifying the buying power of their existing budgets," Hale said. "However, taken as a whole, the various Trump policies could have the impact of raising inflation, particularly impacts stemming from proposed tariffs and reductions in immigration."US President-elect Donald Trump filed a brief Friday urging the Supreme Court to pause a law that would ban TikTok the day before his January 20 inauguration if it is not sold by its Chinese owner ByteDance. "In light of the novelty and difficulty of this case, the court should consider staying the statutory deadline to grant more breathing space to address these issues," Trump's legal team wrote, to give him "the opportunity to pursue a political resolution." Trump was fiercely opposed to TikTok during his 2017-21 first term, and tried in vain to ban the video app on national security grounds. The Republican voiced concerns -- echoed by political rivals -- that the Chinese government might tap into US TikTok users' data or manipulate what they see on the platform. US officials had also voiced alarm over the popularity of the video-sharing app with young people, alleging that its parent company is subservient to Beijing and that the app is used to spread propaganda, claims denied by the company and the Chinese government. Trump called for a US company to buy TikTok, with the government sharing in the sale price, and his successor Joe Biden went one stage further -- signing a law to ban the app for the same reasons. Trump has now, however, reversed course. "Now (that) I'm thinking about it, I'm for TikTok, because you need competition," he recently told Bloomberg. More from this section "If you don't have TikTok, you have Facebook and Instagram -- and that's, you know, that's Zuckerberg." Facebook, founded by Mark Zuckerberg and part of his Meta tech empire, was among the social media networks that banned Trump after attacks by his supporters on the US Capitol on January 6, 2021. The ban was driven by concerns that he would use the platform to promote more violence. Those bans on major social media platforms were later lifted. In the brief filed on Friday, Trump's lawyer made it clear the president-elect did not take a position on the legal merits of the current case. "President Trump takes no position on the underlying merits of this dispute," John Sauer wrote in the amicus curiae -- or "friend of the court" -- brief. "Instead, he respectfully requests that the court consider staying the act's deadline for divestment of January 19, 2025, while it considers the merits of this case, thus permitting President Trump's incoming Administration the opportunity to pursue a political resolution of the questions at issue in the case." ft/aha( MENAFN - GetNews) New track blends diverse musical influences into an optimistic soundscape. Independent musician and guitarist Omer B is pleased to announce the official release of his latest instrumental single, "Dino Puppy Groove," now available through all major streaming platforms and social media channels. The track aims to provide listeners with an uplifting and distinctive musical experience that draws on a wide range of genres, including funk, rock, blues, gospel, pop, and jazz. The new single marks a notable moment in Omer B's evolving career as a musician who seamlessly integrates eclectic influences into a coherent and engaging style. "Dino Puppy Groove" reflects a joyful and open-hearted mood, offering a sound described as both bright and energetic. The title pays subtle homage to two well-regarded bands, Snarky Puppy and Chalk Dinosaur, both of which have inspired Omer B's approach to crafting a fresh and dynamic musical landscape. Recorded and produced to highlight the versatility of Omer B's instrumentation, "Dino Puppy Groove" features his guitar and bass work complemented by the driving percussion of drummer Glenn Welwman. The result is an arrangement that balances technical skill with a clear intent to spark positivity. From the first note, the track encourages an optimistic outlook, suggesting that music can serve as a refreshing escape as well as a source of comfort. Available on Apple Music , Spotify and through DistroKid , the single invites listeners to experience the natural synthesis of different musical traditions. Omer B hopes that this piece will appeal to fans of diverse genres, while also attracting new audiences who value authentic artistic expression. Omer B commented on the new release, "I wanted to create something that radiates warmth and hope, something that feels as playful as it is heartfelt. 'Dino Puppy Groove' is about embracing the natural blend of influences that come together in my music." A longtime supporter of Omer B's work, listener James Carter, remarked on the single, "This track is a reminder that music can transcend categories. It captures so much joy while remaining grounded in a rich and honest sound." For more information visit . About Omer B Omer B is an independent musician and amateur race driver who has cultivated a sound that draws from multiple genres and influences. He has consistently focused on producing music that feels both exploratory and accessible. With a background that includes funk, rock, blues, gospel, pop, and jazz, Omer B aims to create pieces that connect with listeners on a personal level. MENAFN23122024003238003268ID1109025417 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.
BEAVERTON, Ore., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Advantage Media Partners, a top digital marketing agency in Beaverton, Oregon, announces the addition of 15 new team members to strengthen its services, with a primary focus on search engine optimization (SEO). This strategic expansion reflects the company's commitment to helping businesses improve their online visibility, drive organic traffic, and achieve higher rankings on search engines. The new hires will enhance SEO capabilities and support key departments, including Google Advertising, Web Development, and Sales. This growth positions Advantage Media Partners to meet the rising demand for robust digital marketing solutions. "SEO is essential for businesses to stand out in today's competitive online environment," said Nathan Baker, VP of Advantage Media Partners. "Our expanded team enables us to deliver even better results for our clients." Why SEO Matters Advantage Media Partners specializes in delivering SEO strategies that drive measurable results, from increased website traffic to improved search rankings. The agency focuses on in-depth keyword research, on-page optimization, link building, and analytics to provide a comprehensive SEO experience. Local businesses also benefit from the agency's expertise in Local SEO, designed to dominate local search results in Beaverton and beyond. These services are tailored to small and medium-sized businesses looking to grow their digital presence effectively. About Advantage Media Partners Located at 8700 SW Creekside Pl, Beaverton, OR, Advantage Media Partners is a trusted digital marketing agency offering SEO, web design, and social media marketing. Known for its client-focused approach, the company consistently delivers customized strategies that align with business goals. Operating Hours: Monday to Friday, 9:00 AM – 4:00 PM Contact: (888) 475-7532 Website: www.AdvantageMediaPartners.com SEO-Related FAQ 1. Why is SEO important? SEO improves visibility, drives organic traffic, and builds credibility for businesses. 2. Who benefits from your SEO services? Businesses of all sizes, including local service providers and national brands. 3. How can I schedule an SEO consultation? Call (888) 475-7532 or visit our website to book a free consultation. Keywords: SEO services, local SEO experts, boost website traffic, search engine optimization Beaverton. For media inquiries, contact: Eric Wade Advantage Media Partners Email: eric@advantagemediapartners.com Phone: (888) 475-7532 © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.